A new technique that combines bone marrow removal and injection of a hormone helps promote rapid formation of new bone at targeted locations in the body, it was reported by Yale School of Medicine this month in Tissue Engineering.
"This could radically change the way patients are currently treated for weakened or fractured hips, vertebrae and acute traumatic long bone fractures," said senior author Agnès Vignery, associate professor of orthopedics.
She said currently available treatment requires surgery and artificial materials and often results in imperfect outcomes. "The ideal approach would be to create new bone where it is needed and at a faster rate," Vignery said.
The study in mice was done in collaboration with Unigene Laboratories, Inc. It evaluated the effect of bone marrow removal from particular sites followed by daily injections of anabolic agents such as parathyroid hormone (PTH).
The procedure creates new bone tissue that appears structurally and biologically normal and that endows the targeted bone with improved biomechanical properties at a rate and extent that would not be achievable by anabolic therapy alone, Vignery said.
"We have shown that it is the synergistic effect of mechanical marrow ablation and PTH that allows for this new bone to fill the marrow cavity," she said.
She said additional studies are underway that extend the results of this work in other animals and that will determine whether the newly formed bone can be preserved over a long period of time.
Source: Yale University
Related stories:
New Stanford diagnostic test for rare leukemia appears to give faster results, study finds
A new twist on a well-known cell sorting technique may allow physicians to diagnose rare leukemias in hours instead of weeks, according to a study by researchers at the Stanford University School of Medicine and UC-San Francisco. The clinical promise of the Stanford-developed approach, which eavesdrops on individual cells to decipher potentially dangerous molecular conversations, is likely to extend to many other disorders in which cell-signaling pathways are disrupted.
Government probes chelation-heart disease study
(AP) -- The largest alternative medicine study the government has ever launched has stopped enrolling people while officials investigate whether participants were fully informed of the risks and are being adequately protected, The Associated Press has learned.
Scientists develop new, more sensitive nanotechnology test for chemical DNA modifications
Researchers at The Johns Hopkins University School of Medicine in Baltimore have developed a novel test to screen for chemical modifications to DNA known as methylation. The technology potentially could be used both for early cancer diagnoses and for assessing patients' response to cancer therapies.
Resetting immune system in bid to beat scleroderma
(AP) -- First Bari Martz's fingers turned blue. Then she started gasping for breath, and her joints stiffened so that she couldn't even open her hands. Doctors diagnosed scleroderma, part of an insidious family of diseases where the immune system attacks a patient's own body, sometimes enough to kill.
New leukemia signal could point way to better treatment
Cancer researchers at the Stanford University School of Medicine have discovered a promising new chemotherapy target for a deadly form of leukemia. Their discovery hinges on a novel "double agent" role for a molecular signal that regulates cell growth.
Engineered stem cells carry promising ALS therapy
(PhysOrg.com) -- Using adult stem cells from bone marrow as "Trojan horses"to deliver a nurturing growth factor to atrophied muscles, Wisconsin scientists have successfully slowed the progression of ALS in rats.
New synthetic form of protein holds promise to stop cancer spread
Researchers at the Medical College of Wisconsin in Milwaukee have a pending patent on a new synthetic form of a protein involved in certain types of cancers and immune system diseases.
Embryonic stem cells might help reduce transplantation rejection
Researchers have shown that immune-defense cells influenced by embryonic stem cell-derived cells can help prevent the rejection of hearts transplanted into mice, all without the use of immunosuppressive drugs.